Login to Your Account



Another Partner for Halozyme-Pfizer Deal Could Total $515M

By Peter Winter
BioWorld Insight Editor

Wednesday, December 26, 2012
Halozyme Therapeutics Inc. added another feather in its partnership cap with Pfizer Inc. inking a worldwide collaboration and license agreement to develop and commercialize products that combine their recombinant human hyaluronidase enzyme (rHuPH20) with biologics directed to up to six unnamed targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription